
Amphastar Pharma (AMPH) Stock Forecast & Price Target
Amphastar Pharma (AMPH) Analyst Ratings
Bulls say
Amphastar Pharmaceuticals Inc. demonstrated strong performance in its recent quarterly results, with a top-line revenue of $191.8 million for 3Q25, reflecting a 10% sequential increase and a 5% year-over-year growth, driven by robust sales of Baqsimi and Primatene Mist. The company anticipates sustained growth, forecasting high-single digit unit growth for Baqsimi in 2025 and a return to double-digit growth in 2026, highlighting a positive trajectory despite some challenges in glucagon and epinephrine sales. Additionally, Amphastar is optimistic about upcoming product approvals and launches, specifically AMP-015 and AMP-007, expected in the first half of 2026, which could further bolster its market position and revenue streams.
Bears say
Amphastar Pharmaceuticals Inc. is facing a negative outlook due to significant decreases in sales expectations for key products, particularly iron sucrose and glucagon, driven by increased competition and supply issues. The anticipated revenue from iron sucrose has been notably lowered from an annual expectation of $60 million to approximately $20 million, while glucagon sales are projected to fall below $70 million starting in 2026, influenced by new market entrants. Additionally, expectations for robust top-line growth have been moderated, with forecasts shifting from double-digit growth in 2026 to a more subdued range of high-single to low-double digits, reflecting concerns about the company's current pipeline and market positioning.
This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.
Amphastar Pharma (AMPH) Analyst Forecast & Price Prediction
Start investing in Amphastar Pharma (AMPH)
Order type
Buy in
Order amount
Est. shares
0 shares